摘要
近年来，越来越多的研究提示2型糖尿病会增加肿瘤发生风险，这除了与2型糖尿病具有高血糖、高胰岛素血症、胰岛素抵抗、血脂异常、持续的慢性炎症状态等病理特点相关外，还可能与糖尿病患者长期服用磺脲类药物、双胍类药物、格列酮类药物、二肽基肽酶Ⅳ抑制剂、胰升糖素样肽1受体激动剂等降糖药物和使用胰岛素与胰岛素类似物有关。本文就这些因素对肿瘤发生风险的影响进行综述。
[Summary] During recent years, increasing evidences have indicated that type 2 diabetes mellitus（T2DM） might increase the risk of certain tumors; the process might be not only related with the chronic pathologic status of T2DM such as hyperglycemia, hyperinsulinemia, insulin resistance, dyslipidemia, status of chronic inflammation but also associated with the long-term use of anti-diabetic drugs （i. e. sulfonylureas, biguanides, glitazones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptitide-1 receptor agonists）, as well as the use of insulin and insulin analogues. Herewith a system review was made about the recent progress in studying T2DM and tumor risk.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2015年第6期544-547,共4页
Chinese Journal of Endocrinology and Metabolism
基金
国家自然科学基金青年基金项目（81403276）
关键词
糖尿病
2
型
肿瘤
药物
Diabetes mellitus,type 2
Neoplasms
Drugs
